Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Reprogramming alveolar macrophage responses to TGF-β reveals CCR2+ monocyte activity that promotes bronchiolitis obliterans syndrome
Zhiyi Liu, Fuyi Liao, Jihong Zhu, Dequan Zhou, Gyu Seong Heo, Hannah P. Leuhmann, Davide Scozzi, Antanisha Parks, Ramsey Hachem, Derek E. Byers, Laneshia K. Tague, Hrishikesh S. Kulkarni, Marlene Cano, Brian W. Wong, Wenjun Li, Howard J. Huang, Alexander S. Krupnick, Daniel Kreisel, Yongjian Liu, Andrew E. Gelman
Zhiyi Liu, Fuyi Liao, Jihong Zhu, Dequan Zhou, Gyu Seong Heo, Hannah P. Leuhmann, Davide Scozzi, Antanisha Parks, Ramsey Hachem, Derek E. Byers, Laneshia K. Tague, Hrishikesh S. Kulkarni, Marlene Cano, Brian W. Wong, Wenjun Li, Howard J. Huang, Alexander S. Krupnick, Daniel Kreisel, Yongjian Liu, Andrew E. Gelman
View: Text | PDF
Research Article Immunology Inflammation

Reprogramming alveolar macrophage responses to TGF-β reveals CCR2+ monocyte activity that promotes bronchiolitis obliterans syndrome

  • Text
  • PDF
Abstract

Bronchiolitis obliterans syndrome (BOS) is a major impediment to lung transplant survival and is generally resistant to medical therapy. Extracorporeal photophoresis (ECP) is an immunomodulatory therapy that shows promise in stabilizing BOS patients, but its mechanisms of action are unclear. In a mouse lung transplant model, we show that ECP blunts alloimmune responses and inhibits BOS through lowering airway TGF-β bioavailability without altering its expression. Surprisingly, ECP-treated leukocytes were primarily engulfed by alveolar macrophages (AMs), which were reprogrammed to become less responsive to TGF-β and reduce TGF-β bioavailability through secretion of the TGF-β antagonist decorin. In untreated recipients, high airway TGF-β activity stimulated AMs to express CCL2, leading to CCR2+ monocyte-driven BOS development. Moreover, we found TGF-β receptor 2–dependent differentiation of CCR2+ monocytes was required for the generation of monocyte-derived AMs, which in turn promoted BOS by expanding tissue-resident memory CD8+ T cells that inflicted airway injury through Blimp-1–mediated granzyme B expression. Thus, through studying the effects of ECP, we have identified an AM functional plasticity that controls a TGF-β–dependent network that couples CCR2+ monocyte recruitment and differentiation to alloimmunity and BOS.

Authors

Zhiyi Liu, Fuyi Liao, Jihong Zhu, Dequan Zhou, Gyu Seong Heo, Hannah P. Leuhmann, Davide Scozzi, Antanisha Parks, Ramsey Hachem, Derek E. Byers, Laneshia K. Tague, Hrishikesh S. Kulkarni, Marlene Cano, Brian W. Wong, Wenjun Li, Howard J. Huang, Alexander S. Krupnick, Daniel Kreisel, Yongjian Liu, Andrew E. Gelman

×

Figure 2

ECP reprograms AMs to antagonize TGF-β bioavailability.

Options: View larger image (or click on image) Download as PowerPoint
ECP reprograms AMs to antagonize TGF-β bioavailability.
POD16 2T-FVB and...
POD16 2T-FVB and 3T-FVB allograft (A) BALF and plasma analyzed for TGF-β isoform protein content by ELISA (n = 6/group) or (B) activity with a HEK293 SMAD 2/3 luciferase reporter cell line (n = 5/group). AU, arbitrary luciferase units. Data shown for A and B are representative results from 2 experiments. (C) CellTrace633-labeled ECP-treated leukocytes injected into 3T-FVB allograft and analyzed for uptake by intragraft CD11b+ phagocytes. Data shown are representative results from 4 experiments. (D) Heatmap of saline- and ECP-treated POD16 3T-FVB allografts, AM transcript levels of TGF-β signaling, and fibrosis-related gene targets normalized to the macrophage housekeeping gene Stx5a. (n = 4/group) (E) Fold accumulation of TGF-β–induced AM Serpine1 mRNA accumulation in the presence or absence of 10 μM SB43152 or vehicle (DMSO) (n = 4/group). Data shown are normalized to baseline levels (non–TGF-β–treated DMSO-pretreated controls). (F) Saline- and ECP-treated AMs were cultured overnight and analyzed by ELISA for DCN secretion (n = 7/group). (G) TGF-β activity measurements of enriched supernatants from saline- or ECP-treated DCNΔ/Δ and DCNfl/fl AMs cultured with or without 10 ng/ml TGF-β1 (n = 5/group). Data shown in F and G are representative results from 2 experiments. (H) Naive B6 CD4+ T cells were stimulated with plate-bound CD3ε and CD28 Abs in the presence or absence of indicated AM-conditioned supernatants added at a 1:1 v/v ratio to Th17 polarization medium that contained 10 ng/ml TGF-β1 (n = 5/group). Intracellular IL-17A expression was assessed 4 days later. Data are represented as mean ± SD. One-way ANOVA with Dunnett’s multiple-comparison test (A, B, G, and H); 2-sided Mann-Whitney U test (D and F). *P < 0.05; **P < 0.01; ***P < 0.001.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts